EP0162825A2 - Verwendung eines spezifischen karzinomassoziierenden Antigens (Hapten), Fucosylsialosylgangliotetrose (Fuc-GM1) in diagnostischen und therapeutischen Verfahren betreffend den menschlichen Lungenkrebs (Carcinomas von kleinen Zellen) - Google Patents

Verwendung eines spezifischen karzinomassoziierenden Antigens (Hapten), Fucosylsialosylgangliotetrose (Fuc-GM1) in diagnostischen und therapeutischen Verfahren betreffend den menschlichen Lungenkrebs (Carcinomas von kleinen Zellen) Download PDF

Info

Publication number
EP0162825A2
EP0162825A2 EP85850172A EP85850172A EP0162825A2 EP 0162825 A2 EP0162825 A2 EP 0162825A2 EP 85850172 A EP85850172 A EP 85850172A EP 85850172 A EP85850172 A EP 85850172A EP 0162825 A2 EP0162825 A2 EP 0162825A2
Authority
EP
European Patent Office
Prior art keywords
antigen
fuc
use according
specific
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP85850172A
Other languages
English (en)
French (fr)
Other versions
EP0162825A3 (en
EP0162825B1 (de
Inventor
Jan Roland Holmgren
Leif Gustav Lindholm
Lars Torvald Svennerholm
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Health AB
Original Assignee
Pharmacia AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia AB filed Critical Pharmacia AB
Priority to AT85850172T priority Critical patent/ATE61734T1/de
Publication of EP0162825A2 publication Critical patent/EP0162825A2/de
Publication of EP0162825A3 publication Critical patent/EP0162825A3/en
Application granted granted Critical
Publication of EP0162825B1 publication Critical patent/EP0162825B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4614—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464469—Tumor associated carbohydrates
    • A61K39/464471—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6006—Cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/622—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier non-covalent binding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2474/00—Immunochemical assays or immunoassays characterised by detection mode or means of detection
    • G01N2474/20—Immunohistochemistry assay
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/813—Cancer

Definitions

  • This invention relates to the use of a specific carcinoma associated antigen/hapten of carbohydrate nature, fucosylsialosylgangliotetraose-IV 2 ⁇ Fucll 3 ⁇ NeuAcGgOse 4 -(IUPAC-IUB Lipid Document, 1977) for diagnostic and therapeutic procedures related to human lung cancer (small cell carcinomas).
  • glycoconjugates carbohydrate structures
  • the cell surface carbohydrates are linked either to a lipid moiety, in which case they are called glycolipids, or to peptides (proteins), in which case they are called glycopeptides (glycoproteins).
  • Tumor-associated glycoconjugate antigens are previously known in relation to human cancer disease. In melanomas the carbohydrate structures disialosylgangliotetraose and disialosyllactose have been identified linked to a lipid portion. Two carcinoma associated antigens CEA (carcinoembryonal antigen) and GICA (gastrointestinal cancer antigen) have been demonstrated particularly in gastrointestinal carcinomas while a third antigen, CA-50, seems to have a more general distribution. All the antigens are shedded from the cell surface or secreted from the tumor cell and can be demonstrated in blood serums by means of immunological methods.
  • CEA carcinoma associated antigen
  • GICA gastrointestinal cancer antigen
  • the present invention is based on the discovery that patients with certain forms of lung cancer (small cell carcinomas or oat-cell carcinoma) express in the primary lung tumor and its metastases an acidic glycolipid, which is not expressed in normal lung tissue.
  • This glycolipid antigen is a ganglioside with the complete chemical structure Fuc ⁇ 1-2Gal ⁇ 1-3GalNAc ⁇ 1-4(NeuAc ⁇ 2-3)Gal ⁇ 1-4Glc-Cer or IV 2 aFucll 3 ⁇ NeuAcGgOse 4 Cer with the short designation Fuc-GM1 (IUPAC-IUB Lipid Document, 1977).
  • This ganglioside was first isolated from bovine brain (Ghidoni et al., J. Neurochem.
  • ganglioside Fuc-GM1 in pure form from human cancer tissue and from animal organ.
  • the purified ganglioside has by a special device obtained an increased immunogenic activity and then been used for the production of monoclonal antibodies.
  • Procedures have, within the scope of the invention, been developed for the identification and quantitative determination in tissues, tissue sections, cytological preparations and various body fluids. All of these methods for diagnostic purposes are based on the fact that the antigen can be detected and quantitatively determined by the reaction with specific antibodies produced against the pure ganglioside antigen, Fuc-GM1.
  • ganglioside antigen can be measured: surgical or autopsy material of lung, liver, brain or similar organs, cytological specimens obtained by biopsy of lung or other organs, where signs of cancer metastases can be suspected, cells, obtained by aspirations of the respiratory tract, expectorations, or by puncture of pleural or abdominal cavity, biological fluids like whole blood, blood plasma or serum, lymph, cerebrospinal fluid, urine, saliva or similar.
  • the antigen which Is used in the present invention is termed, fucosylsialosylgangliotetraose and has the following chemical structure: Fuc ⁇ 1-2Gal ⁇ 1-3GalNAc ⁇ 1-4(NeuAc ⁇ 2-3)Gal ⁇ 1-4Glc or IV 2 ⁇ Fucll 3 ⁇ NeuAcGgOse 4 (IUPAC-IUB Lipid Document, 1977).
  • all antigens, which have been modified by the removal of the terminal glucose moiety or by the substitution of the sialic acid (NeuAc) moiety to the N-acetylgalactosamine (GaINAc) moiety instead of to the galactose (Gal) moiety are covered by this patent application.
  • the monoclonal antibodies referred to in the present invention have all been produced from antigens bound to a lipid group (acylsphingosine) but this claim will also include the binding of the antigenic group to every other compound.
  • the antigen which has been used in the present invention can be isolated from tumor tissue, obtained by surgery or autopsy of patients with lung small cell carcinoma.
  • concentration of the antigen in the tumor tissue is in general relatively low, particularly when the patient has been treated with cytostatic drugs, and the isolation of the antigen will then be laborious.
  • another biological material which can be used for the isolation of the cancer antigen.
  • high concentrations of the ganglioside antigen is formed in the pig's central nervous system, particularly In the dorsal root ganglia.
  • the cancer associated ganglioside antigen can then be relatively simply isolated from brain and dorsal roof ganglia.
  • gangliosides - it means glycolipids containing sialic acid - are poor immunogens and it has been difficult to produce antibodies with high affinity and specificity against them. This difficulty has been circumvented in the present invention by the adsorption of the ganglioside antigen to a bacterial membrane with known high immunogenic activity. By this device a large number of monoclonal antibodies with high specificity and affinity against the cancer antigen have been produced.
  • the present invention concerns in accordance herewith a procedure for the induction of the cancer associated antigen fucosylsialosylgangliotetraose in the nervous system of a particular type of miniature pig, isolation of the antigen with chromato- graphical methods and production of monoclonal antibodies against the purified antigen adsorbed to a certain bacterial membrane.
  • the invention includes also the use of the compound fucosylsialosylgangliotetraose and all the derivates of this substance and all types of antibodies directed against them for the diagnosis of different cancer forms, specially certain forms of lung cancer, and for the treatment of the cancer disease in patients.
  • Miniature pigs type Göttingen, with a weight of 20-30 kg, were given a diet, in which the regular fodder was supplemented with 30 g chloroquine diphosphate per kg fodder.
  • the different ingredients were mixed under the addition of water and after careful mixing the fodder was pelletted and dried.
  • the pigs were given this fodder for 2 months and were then slaughtered (bieed- ing under narcosis).
  • the whole nervous system was collected, including retina and dorsal root ganglia. Brain and dorsal ganglioa + retina were processed separately, since dorsal ganglia and retina had approx. 20 times higher concentration of Fuc-GM1 than brain.
  • the tissue was homogenized after the addition of 3 volumes of water to one volume of tissue material. After homogenization with a knife homogenizer at 1500 rpm during 3 min., 10 volumes of methanol was added under continuous stirring. Then 5 volumes of chloroform were added. After extraction for 1 h the clear supernatant was isolated by centrifugation at 2000 rpm. To the supernatant was added water to give a final chloroform-methanol-water ratio 4:8:5.6 (by volume). After mixing in a separatory funnel, two distinct phases appeared. The upper phase was collected and evaporated to dryness after the addition of 0.1 1 volume or butanol to prevent foaming.
  • the evaporation was performed with a rotaratory evaporator under gentle warming on a water bath, the temperature not exceeding 50°C.
  • the residue was added 0.5 volume methanol per volume original tissue and 0.5 volume of 1.0 M potassium hydroxide and was left overnight at room temperature.
  • the alkaline solution was neutralized to pH 8 with 1.0 M hydrochloric acid and was then allowed to dialyse against running tap water for 48 hours.
  • the dialysed crude ganglioside fraction was evaporated (lyophilized) and dissolved 1 volume of chloroform-methanol-water with a volume ratio of 60:30:4.5 per volume original tissue.
  • a column (inner diameter 20 mm) was packed with Spherosil-DEAE-dextran, 0.2 volume of resin per volume of original tissue.
  • the dialysed ganglioside extract was added slowly to the column and the column was then eluted with 10 bed volumes of chloroform-methanol-water (60:30:4.5, by volume).
  • the monosialoganglioside fraction was eluted with 10 bed volumes of 0.02 M potassium acetate in methanol.
  • the monosialoganglioside fraction was evaporated and desalted by dialysis against distilled water.
  • silica gel (latrobeads ®) was used for each g of original nervous tissue.
  • the gel was suspended in chloroform-methanol (volume ratio 4:1) and poured into a glass column with a sintered glass filter and a diameter of 15-20 mm depending on the amount of gel.
  • the ganglioside fraction was dissolved in 10 ml of chloroform-methanol-water (65:25:4, by volume) and applied to the column. It was eluted first with 15 ml of chloroform-methanol-water (65:25:4, by volume) for each g (weight/volume) of gel, which was collected in one fraction.
  • Fuc-GM1 The final purification of Fuc-GM1 was achieved by preparative thin-layer chromatography.
  • Ganglioside (5 ⁇ moles) was applied on a thin-layer plate (20x20 cm, 0.25 mm thick, Merck, AG., Darmstadt), which was developed for 60 min with chloroform-methanol-2.5 M ammonia at 21°C. After completed chromatography the plate was sprayed with 0.01% bromthymol blue in water and the Fuc-GMI band was scraped off.
  • the ganglioside was eluted from the gel with chloroform-methanol-water (30:60:20, by volume) and was added one drop of 0.1 M potassium hydroxide dissolved in methanol and evaporated to dryness.
  • the pure ganglioside Fuc-GM1 was kept dry in a vacuum desiccator or was dissolved in a small volume of chloroform-methanol (2:1, by volume) and was kept in a teflon capped tube in the dark at +4°C.
  • the purified ganglioside Fuc-GM1 from Example 1 was adsorbed to acid-washed Salmonella Minnesota bacteria before immunization according to the principle, described by Young, W.W. and collaborators (J. Exp. Med. 150, 1008-1019, 1979).
  • mice 6-8 weeks old, were immunized intravenously with 5 ⁇ g of ganglioside Fuc-GM1, adsorbed to 50 ⁇ g acid-washed Salmonella Minnesota bacterial membranes, suspended in 100 ⁇ l of phosphate-buffered physiological saline, pH 7.4. A new immunization was performed after two weeks with the same dose of immuno- gen under identical conditions (booster dose).
  • the spleen cells taken from the immunized mice were fused with mouse Sp 2/0 myeloma cells.
  • the resulting hybridomas were expanded, tested and cloned according to the protocol, devised by de St. Groth and Scheid- egger (J. Immunol. Methods, 1-21, 1980).
  • the culture medium was collected from each microtiter well with growing hybridomas to determine those secreting antibody specific for Fuc-GM1.
  • the determination was performed in an ELISA system according to the following procedure: Fuc-GM1, 50 pmol dissolved in 50 ⁇ l of methanol, was added to the wells of a polyvinylmicrotiter plate and evaporated to dryness.
  • the Fuc-GMI positive/HuLy-c negative hybrids were cloned by limited dilution and expanded. The culture medium was collected and used for additional tests without further processing. The isotype of the antibodies produced by each clone was determined by single radial immunodiffusion in agarose containing isotype specific antimouse immunoglobulins.
  • the Fuc-GM1 positive/HuLy-c negative hybridomas were cloned and screened to determine those secreting antibody specific for Fuc-GM1. The determination was performed in a double antibody solid phase radioimmuno assay. Fuc-GM1 and a large number of different neutral glycolipids and gangliosides were dissolved in methanol and pipetted into the wells of microtiter plates. After evaporation of the solvents the antigen coated wells were incubated with the monoclonal antibodies. Bound antibody was detected with 125 I-labelled antimouse immunoglobulin; 125 I-antimouse IgM or 125 I-antimouse lgaF(ab) 2 fragment. Each monoclonal antibody was tested against Fuc-GM1; a standard mixture of human brain gangliosides, normal lung tissue, neutral glycolipids and gangliosides.
  • the specificity of the monoclonal antibodies were also determined by thin-layer chromatographic immunostaining of the glycolipid antigens.
  • the total neutral and acidic glycolipid fractions from a number of organs were separated on aluminia-backed high performance thin-layer plates (HPTLC) and incubated with the monoclonal antibodies of the Fuc-GM1 positive hybridomas, diluted with Tris buffer-1% BSA (0.05 M Tris, 0.14 M NaCI, pH 7.8, containing 10 g bovine serum albumin/I and 100 mg merthiolate/I).
  • Bound monoclonal antibody was detected with 125 I-labelled antimouse immunoglobulin and then exposing it to X-ray film for 12-24 h.
  • the antibodies were applied to the plate by soaking cellulose acetate strips in the antibody solution and covering one lane of the HPTLC-plate with the strip.
  • Tissue approx. 0.1 g
  • Tissue was homogenized together with 0.5 ml of water in a small conical tube tissue grinder with teflon pestle in an ice bath.
  • 1.6 mt of methanol and 0.8 ml of chloroform were added.
  • the clear supernatant was transferred to a Kimax-tube with teflon cap.
  • the sediment was suspended in 0.5 ml of water and then 1.6 ml of methanol and 0.8 ml of chloroform were added.
  • a portion of the antigen fraction was dissolved in methanol and 50 ⁇ l of extract was pipetted into the wells of a polyvinyl microtiter plate. Standard solutions of 0.5 to 5 pmol of pure Fuc-GM1 in methanol was added to other wells. The solvent was evaporated under a stream of nitrogen. To the unknown samples and standards 10-100 ug of monoclonal antibody, specific for Fuc-GM1 and produced as described in Example 2, dissolved in PBS/BSA was added. The samples were incubated for 1 h at room temperature. The wells were washed 3 times with PBS solution and then 125 I-labelled antimouse-immunoglobulin was added and allowed to react for 3 hours.
  • Fuc-GM1 has been detected in 19/20 lung small cell carcinoma.
  • the antigen has not been identified in other forms of lung carcinomas (squamous cell, large cell or adenocarcinoma) neither in carcinomas of mammary gland, stomach, colorectal mucosa, urinary bladder or uterus. Traces of the antigen has been shown in normal and carcinomatous pancreatic tissue.
  • the concentration of tumor antigen was determined with a double solid phase antibody method, at which the antigen was adsorbed to the solid phase and determined with the specific monoclonal antibody (Example 2) and antimouse-immunoglobulin.
  • Fuc-GM1 (20 pmol) and the purified antigen fraction of unknown serum samples were dissolved in methanol and serial dilutions of them (1/2-1/2048) were pipetted in the wells of polyvinyl microtiter plates (Flow Laboratories art.nr. 77-173-05) and were evaporated. Unspecific binding of the wells was blocked with 20 ⁇ l of 1% BSA in PBS and then 50 ⁇ l of specific monoclonal antibody, diluted in 1% BSA in PBS, was added.
  • the antigen was only detected in blood serum of patients with lung small cell carcinoma.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Optics & Photonics (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP85850172A 1984-05-18 1985-05-15 Verwendung eines spezifischen karzinomassoziierenden Antigens (Hapten), Fucosylsialosylgangliotetrose (Fuc-GM1) in diagnostischen und therapeutischen Verfahren betreffend den menschlichen Lungenkrebs (Carcinomas von kleinen Zellen) Expired - Lifetime EP0162825B1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AT85850172T ATE61734T1 (de) 1984-05-18 1985-05-15 Verwendung eines spezifischen karzinomassoziierenden antigens (hapten), fucosylsialosylgangliotetrose (fuc-gm1) in diagnostischen und therapeutischen verfahren betreffend den menschlichen lungenkrebs (carcinomas von kleinen zellen).

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE8402702 1984-05-18
SE8402702A SE468231B (sv) 1984-05-18 1984-05-18 Foerfarande foer att paavisa smaacelligt lungcarcinomantigen och anvaendning av antikroppar mot fukosylsialosylgangliotetraos foer framstaellning av komposition foer behandling eller in vivo/ diagnos

Publications (3)

Publication Number Publication Date
EP0162825A2 true EP0162825A2 (de) 1985-11-27
EP0162825A3 EP0162825A3 (en) 1987-10-07
EP0162825B1 EP0162825B1 (de) 1991-03-20

Family

ID=20355939

Family Applications (1)

Application Number Title Priority Date Filing Date
EP85850172A Expired - Lifetime EP0162825B1 (de) 1984-05-18 1985-05-15 Verwendung eines spezifischen karzinomassoziierenden Antigens (Hapten), Fucosylsialosylgangliotetrose (Fuc-GM1) in diagnostischen und therapeutischen Verfahren betreffend den menschlichen Lungenkrebs (Carcinomas von kleinen Zellen)

Country Status (6)

Country Link
US (1) US4888275A (de)
EP (1) EP0162825B1 (de)
JP (1) JPS6193A (de)
AT (1) ATE61734T1 (de)
DE (1) DE3582191D1 (de)
SE (1) SE468231B (de)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5091178A (en) * 1986-02-21 1992-02-25 Oncogen Tumor therapy with biologically active anti-tumor antibodies
US5242824A (en) * 1988-12-22 1993-09-07 Oncogen Monoclonal antibody to human carcinomas

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57194876A (en) * 1981-05-21 1982-11-30 Seiko Seiki Co Ltd Controlling method of grinding machine
US5122450A (en) * 1985-10-24 1992-06-16 Research Corporation Limited Biochemical reagent
DE4006308A1 (de) * 1990-02-28 1991-08-29 Sandoz Ag Verwendung des monoklonalen antikoerpers br 55.2 gegen kleinzelliges lungenkarzinom
ATE244888T1 (de) * 1993-02-05 2003-07-15 Epigen Inc Humanes carcinoma-antigen (hca), hca antikörper, hca immunoassays, aufzeichnungsmethoden und therapy
EP2239582A1 (de) * 2009-04-09 2010-10-13 Nederlandse Organisatie voor toegepast -natuurwetenschappelijk onderzoek TNO Testsystem zur Bestimmung der Bindung an hydrophobe Arzneimittel

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0106285A2 (de) * 1982-10-08 1984-04-25 Otsuka Pharmaceutical Co., Ltd. Glycosidische Verbindung bezüglich Antigen, Verfahren zur Herstellung und diese enthaltende Antikrebsmittel
EP0118365A2 (de) * 1983-03-04 1984-09-12 Health Research, Inc. Monoklonale Antikörper gegen humane Brustkarzinomzellen und ihre Verwendung in der Diagnose und Therapie
WO1984004599A1 (en) * 1983-05-18 1984-11-22 Us Health Monoclonal antibodies against non small cell lung cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3202894A1 (de) * 1982-01-29 1983-08-11 Otsuka Pharmaceutical Co. Ltd., Tokyo Verfahren zur bestimmung von tumor-assoziierten glykoprotein enthaltenden verbindungen, anwendung des verfahrens zur krebsdiagnose und kit fuer die anwendung des verfahrens
US4725557A (en) * 1982-06-03 1988-02-16 Otsuka Pharmaceutical Co., Ltd. Production of fucosyl antigens and antibodies for recognizing same determination of cancer associated carbohydrate linkage using same and kit for the determination
JPS6057254A (ja) * 1983-09-09 1985-04-03 Dainabotsuto Kk 免疫学的測定法による糖脂質の定量方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0106285A2 (de) * 1982-10-08 1984-04-25 Otsuka Pharmaceutical Co., Ltd. Glycosidische Verbindung bezüglich Antigen, Verfahren zur Herstellung und diese enthaltende Antikrebsmittel
EP0118365A2 (de) * 1983-03-04 1984-09-12 Health Research, Inc. Monoklonale Antikörper gegen humane Brustkarzinomzellen und ihre Verwendung in der Diagnose und Therapie
WO1984004599A1 (en) * 1983-05-18 1984-11-22 Us Health Monoclonal antibodies against non small cell lung cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 100, no. 25, 18th June 1984, page 420, abstract no. 207631k, Columbus, Ohio, US; Y. FUKUSHI et al.: "Novel fucolipids accumulating in human adenocarcinoma. II. Selective isolation of hybridoma antibodies that differentially recognize mono-, di-, and trifucosylated type 2 chain"; & J. BIOL. CHEM. 1984, 259(7), 4681-5 *
CHEMICAL ABSTRACTS, vol. 103, no. 7, 19th August 1985, page 402, abstract no. 52062m, Columbus, Ohio, US; O. NILSSON et al.: "Fucosyl-Gm1 - a ganglioside associated with small cell lung carcinomas"; & GLYCOCONJUGATE J. 1984, 1(1), 43-9 *
CHEMICAL ABSTRACTS, vol. 98, no. 5, 31st January 1985, page 504, abstract no. 32675p, Columbus, Ohio, US; J.L. MAGNANI et al.: "A monoclonal antibody-defined antigen associated with gastrointestinal cancer is a ganglioside containing sialylated lacto-N-fucopentaose II"; & J. BIOL. CHEM. 1982, 257(23), 14365-9 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5091178A (en) * 1986-02-21 1992-02-25 Oncogen Tumor therapy with biologically active anti-tumor antibodies
US5242824A (en) * 1988-12-22 1993-09-07 Oncogen Monoclonal antibody to human carcinomas

Also Published As

Publication number Publication date
SE8402702L (sv) 1985-11-19
SE8402702D0 (sv) 1984-05-18
EP0162825A3 (en) 1987-10-07
JPS6193A (ja) 1986-01-06
DE3582191D1 (de) 1991-04-25
EP0162825B1 (de) 1991-03-20
ATE61734T1 (de) 1991-04-15
US4888275A (en) 1989-12-19
SE468231B (sv) 1992-11-23

Similar Documents

Publication Publication Date Title
US4851511A (en) Monoclonal antibody that specifically binds to disialosyl Lea
Holmgren et al. Comparison of receptors for cholera and Escherichia coli enterotoxins in human intestine
US5240833A (en) Method for the production of monoclonal antibodies directed to tumor-associated gangliosides and fucogangliosides
Rahman et al. A monoclonal antibody specific for the Thomsen-Friedenreich cryptic T antigen.
AU3349089A (en) Carcinoma orosomucoid-related antigen, a monoclonal antibody thereto, and their uses
JPS62190074A (ja) ヒトの癌に付随したジフコガングリオシドを規定するハイブリド−マ抗体
EP0173663B1 (de) Verwendung eines spezifischen tumorassoziierten Antigens, Sialosyllactotetraose, in Diagnose- oder Therapieverfahren bezüglich Krebskrankheiten
EP0381310A1 (de) Monoklonale Antikörper gegen Tumor-assoziierte Ganglioside und Fucoganglioside sowie Produktionsmethode
PT81040B (en) Process for preparing new monoclonal antibodies to glycoconjugates
Kannagi et al. Recent studies of glycolipid and glycoprotein profiles and characterization of the major glycolipid antigen in gastric cancer of a patient of blood group genotype pp (Tja-) first studied in 1951
Knowles et al. Monoclonal anti‐Type 2 H: an antibody detecting a precursor of the A and B blood group antigens
US4757003A (en) Method for the detection of cancer
JP3066741B2 (ja) 癌細胞の増殖及び複製を抑制するための組成物
EP0162825B1 (de) Verwendung eines spezifischen karzinomassoziierenden Antigens (Hapten), Fucosylsialosylgangliotetrose (Fuc-GM1) in diagnostischen und therapeutischen Verfahren betreffend den menschlichen Lungenkrebs (Carcinomas von kleinen Zellen)
Okada et al. Glycolipid antigens with blood group I and i specificities from human adult and umbilical cord erythrocytes.
US4962187A (en) Common antigen for colorectal and mucinous ovarian tumors and process for isolating the same
Chism et al. Evidence for common and distinct determinants of colon carcinoembryonic antigen, colon carcinoma antigen-III, and molecules with carcinoembryonic antigen activity isolated from breast and ovarian cancer
Harvey et al. Immunochemical studies on carcinoembryonic antigen-reactive glycoproteins from carcinomas of the colon and breast separated by concanavalin A affinity chromatography
US5011920A (en) Disialofucoganglioside immunogen and fucoganglioside monosialosyl Lea II
CA2224460C (en) Process for producing gm2 specific antibodies
US4748112A (en) Methods and compositions relating to regression-associated antigens
Hattori et al. Characterization of Glycolipids from the Gastric Cancer of a Patient of p, O, Le (1-, b+) Blood Type: Presence of Incompatible Blood Group Antigens in Tumor Tissues
PAK et al. Identification and isolation of Lewis blood group antigens from human saliva using monoclonal antibodies
EP0255367A2 (de) Krebszellen spezifische monoklonale Antikörpern und entsprechende Hybridomas, ihre Herstellung und Anwendung
LEONI et al. The antitumor monoclonal antibody MOv2 recognizes the Lewis A hapten

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Designated state(s): AT BE CH DE FR GB IT LI LU NL

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE FR GB IT LI LU NL

17P Request for examination filed

Effective date: 19871107

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PHARMACIA AB

17Q First examination report despatched

Effective date: 19891013

DIN1 Information on inventor provided before grant (deleted)
GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE FR GB IT LI LU NL

REF Corresponds to:

Ref document number: 61734

Country of ref document: AT

Date of ref document: 19910415

Kind code of ref document: T

REF Corresponds to:

Ref document number: 3582191

Country of ref document: DE

Date of ref document: 19910425

ET Fr: translation filed
ITF It: translation for a ep patent filed

Owner name: GUZZI E RAVIZZA S.R.L.

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
EPTA Lu: last paid annual fee
REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 19960507

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 19960510

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 19960513

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 19960514

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 19960528

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 19960529

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 19960601

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 19960625

Year of fee payment: 12

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19970515

Ref country code: GB

Effective date: 19970515

Ref country code: AT

Effective date: 19970515

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19970531

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19970531

Ref country code: BE

Effective date: 19970531

BERE Be: lapsed

Owner name: PHARMACIA A.B.

Effective date: 19970531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Effective date: 19971201

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 19970515

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19980130

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 19971201

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19980203

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST